The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy.

DPP-4is were selected as the active comparator because the drugs are used at a similar stage of ... risk for thyroid cancer was observed between the groups (HR, 0.81; CI, 0.59-1.12), with results ...

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...

In this issue of The Lancet Diabetes & Endocrinology, Michelle M Chen and colleagues1 report their findings on trends in the incidence of thyroid cancer in the USA from 1975 to 2019. The authors show ...

No difference in thyroid cancer risk was found for adults with type 2 diabetes using a GLP-1 receptor agonist vs. those using a DPP-IV inhibitor. Women may have a lower risk for thyroid cancer ...

While doctors haven’t pinpointed exact causes, certain factors significantly increase your chances of developing thyroid cancer. Women face three times higher risk than men, particularly between ...

Despite efforts to curb overdiagnosis of thyroid cancer, the issue has continued to plague U.S. healthcare, according to results from a retrospective, population-based study.

The numbers of patients diagnosed with thyroid cancer were 0.17% in the GLP-1 RA group, 0.23% in the DPP4i group, 0.17% in the SGLT2i group, and 0.20% in the sulfonylurea group. (HealthDay News ...

However, overall, the absolute risk for thyroid cancer is low. (HealthDay News) — The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist ...